After striking radiopharmaceutical supply deals with pharma giants Novartis and AstraZeneca within the last six months, Niowave is taking steps to meet growing demand for the alpha-emitting is | Niowave has broken ground on a $75 million facility at its campus in Lansing, Michigan, which will produce Actinium-225. The radioisotope supplier expects the facility to become operational in 2028 and to employ 70 people.